Portola Pharmaceuticals (PTLA) Receives Analyst Rating

Portola Pharmaceuticals (PTLA) : Zacks Investment Research ranks Portola Pharmaceuticals (PTLA) as 3, which is a Hold recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. The average broker rating of 3 research analysts is 1.17, which indicates as a Strong Buy.

Portola Pharmaceuticals (PTLA) : The most positive equity analysts on Portola Pharmaceuticals (PTLA) expects the shares to touch $40, whereas, the least positive believes that the stock will trade at $28 in the short term. The company is covered by 2 Wall Street Brokerage Firms. The average price target for shares are $34 with an expected fluctuation of $8.49 from the mean.


Also, Brokerage firm Morgan Stanley maintains its rating on Portola Pharmaceuticals (NASDAQ:PTLA). As per the latest information, the brokerage house lowers the price target to $28 per share from a prior target of $61. The shares have been rated Overweight. The rating by the firm was issued on August 19, 2016.

Portola Pharmaceuticals (NASDAQ:PTLA): After opening at $22.49, the stock dipped to an intraday low of $22.28 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $23.08 and the buying power remained strong till the end. The stock closed at $23.03 for the day, a gain of 2.40% for the day session. The total traded volume was 599,031. The stocks close on the previous trading day was $22.49.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Companys two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company has a program of selective Syk inhibitors, which is partnered with Biogen Idec Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa. Andexanet alfa is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor. Cerdulatinib is an orally available, potent dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.